

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Roberto Angelo Motterlini *et al.*
Serial No.: 10/535,508
Confirmation No.: 7230
Filed: December 16, 2005
For: THERAPEUTIC DELIVERY OF CARBON MONOXIDE TO
EXTRACORPOREAL AND ISOLATED ORGANS
Examiner: A. Soroush
Art Unit: 1617

Certificate of Electronic Filing Under 37 CFR § 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: March 11, 2011

Signature: /Amelia S. Lennon/ (Amelia S. Lennon)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, the attention of the U.S. Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR § 1.114 (37 CFR § 1.97(b)(4)). Therefore, no fee or certification is required.

Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and this

communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

Applicant submits herewith copies of non-patent literature in accordance with 37 CFR § 1.98(a)(2).

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication, or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98, and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency, or credit any overpayment, in the fees due to our Deposit Account No. 23/2825, under Docket No. H0817.70001US00.

Dated: March 11, 2011

Respectfully submitted,

By /C. Hunter Baker/
C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
617.646.8000